跳至主要内容
临床试验/NCT01341353
NCT01341353Unknown4 期

Atrial Fibrillation Therapy: A Multi-Center Clinical Study

Wuhan University1 个研究点 分布在 1 个国家目标入组 1,800 人开始时间: 2011年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
1,800
试验地点
1
主要终点
Number of participants with all-cause death

研究概览

简要总结

The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients who are willing to enroll in the trial

排除标准

  • 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman

研究组 & 干预措施

Antiarrythmic Drugs

Active Comparator

干预措施: Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists (Drug)

ablation

Experimental

干预措施: catheter ablation (Procedure)

结局指标

主要结局

Number of participants with all-cause death

时间窗: 36 month

severe blooding complications

时间窗: 36 month

cardio-cerebrovascular complications

时间窗: 36 month

Number of participants with cardiovascular death events

时间窗: 36 month

次要结局

  • recurrence of atrial arrhythmias (AF, AFL, AT)(36 month)
  • resource utilization and costs(36 month)

研究者

发起方
Wuhan University
申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Catheter Ablation Versus Antiarrythmic Drugs for... | 临床试验